Which approach is used to identify lead compounds efficiently and at reasonable cost in early drug discovery?

Which approach is used to identify lead compounds efficiently and at reasonable cost in early drug discovery?

• A. Lead Identification Through Virtual Screening
• B. Random Compound Sampling
• C. Clinical Trial Expansion
• D. Animal Model Screening

Answer: (A)

In early drug discovery, the goal is to quickly and cheaply find molecules that are likely to interact with a target. Virtual screening does this by using computer models of the target (structure-based) or known active compounds (ligand-based) to evaluate vast libraries of chemicals. It predicts how well each compound might bind or affect the target, allowing you to rank and select a small set of promising candidates for experimental testing. This dramatically reduces the number of compounds that must be synthesized or purchased and tested in the lab, cutting time and cost compared with trying random or unscreened compounds. Random Compound Sampling isn’t targeted, so it wastes resources by testing many molecules with little to no reason to expect activity. Clinical trials come much later in development and are expensive and lengthy, not a tool for identifying initial leads. Animal model screening can provide valuable in vivo insight but is resource-intensive and not suitable as the primary, efficient method for early lead identification.

In early drug discovery, the goal is to quickly and cheaply find molecules that are likely to interact with a target. Virtual screening does this by using computer models of the target (structure-based) or known active compounds (ligand-based) to evaluate vast libraries of chemicals. It predicts how well each compound might bind or affect the target, allowing you to rank and select a small set of promising candidates for experimental testing. This dramatically reduces the number of compounds that must be synthesized or purchased and tested in the lab, cutting time and cost compared with trying random or unscreened compounds.

Random Compound Sampling isn’t targeted, so it wastes resources by testing many molecules with little to no reason to expect activity. Clinical trials come much later in development and are expensive and lengthy, not a tool for identifying initial leads. Animal model screening can provide valuable in vivo insight but is resource-intensive and not suitable as the primary, efficient method for early lead identification.